文献速递消化系统肿瘤

LOAd703溶瘤病毒免疫刺激基因治疗联合化疗治疗不可切除或转移性胰腺癌(LOKON001):非随机单中心1/2期研究第1组结果

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
PubMed 文献 · Lancet Oncol · 2024-01-01

LOKON001是在美国贝勒医学院Dan L Duncan综合癌症中心开展的非随机1/2期研究,第1组纳入21例不可切除或转移性胰腺导管腺癌患者,接受标准白蛋白结合型紫杉醇联合吉西他滨化疗及瘤内注射LOAd703。联合治疗可行且安全,未达到最大耐受剂量,剂量3为联合化疗时最高评估安全剂量;18例可评估患者中8例(44%,95%CI 25-66)客观缓解。

要点

  • LOAd703联合白蛋白结合型紫杉醇加吉西他滨在晚期胰腺导管腺癌中可行且安全
  • 未达到最大耐受剂量,剂量3(5×10^11病毒颗粒/次)为联合化疗时最高评估安全剂量
  • 18例可评估患者中8例(44%,95%CI 25-66)达客观缓解

核心结论

  • LOAd703联合白蛋白结合型紫杉醇加吉西他滨治疗晚期胰腺导管腺癌可行且安全;为发展这一新型化学免疫治疗策略,LOKON001第2组(LOAd703联合白蛋白结合型紫杉醇加吉西他滨及阿替利珠单抗)正在进行中。

研究设计与样本

  • LOKON001为在美国德克萨斯州休斯顿贝勒医学院Dan L Duncan综合癌症中心开展的非随机1/2期研究,分两组序贯进行,本文报告第1组结果。
  • 第1组纳入18岁及以上既往接受过治疗或未经治疗的不可切除或转移性胰腺导管腺癌患者,接受标准28天周期静脉白蛋白结合型紫杉醇125 mg/m2加吉西他滨1000 mg/m2(最多12周期)及每2周瘤内注射LOAd703。
  • 采用贝叶斯最优区间设计将患者分配至LOAd703 5×10^10(剂量1)、1×10^11(剂量2)或5×10^11(剂量3)病毒颗粒/次,每次注射500 μL,经内镜或经皮注入胰腺肿瘤或转移灶,共注射6次。
  • 主要终点为至少接受一剂LOAd703患者的安全性和治疗 emergent 免疫反应,抗肿瘤活性为次要终点;研究注册号ClinicalTrials.gov NCT02705196。
  • 2016年12月2日至2019年10月17日评估23例患者资格,22例入组,1例撤回知情同意,最终21例(男性13例[62%],女性8例[38%])分配至剂量组(剂量1三例、剂量2四例、剂量3十四例),21例可评估安全性。

主要发现

  • 中位随访时间6个月(IQR 4-10),数据截止日期为2023年1月5日。
  • 总体最常见的治疗 emergent 不良事件为贫血(96/1237事件[8%])、淋巴细胞减少(86事件[7%])、高血糖(70事件[6%])、白细胞减少(63事件[5%])、高血压(62事件[5%])和低白蛋白血症(61事件[5%])。
  • 归因于LOAd703的最常见不良事件为发热(14/21例[67%])、疲乏(8例[38%])、寒战(7例[33%])和肝酶升高(丙氨酸氨基转移酶5例[24%]、碱性磷酸酶4例[19%]、天冬氨酸氨基转移酶4例[19%]),均为1-2级,除剂量3发生一过性3级转氨酶升高外。
  • 未达到最大耐受剂量,从而确定剂量3为联合白蛋白结合型紫杉醇加吉西他滨时最高评估安全剂量。
  • 在可进行T细胞检测的16例患者中,15例(94%)LOAd703注射后CD8+效应记忆细胞和腺病毒特异性T细胞比例增加;可评估活性的18例患者中8例(44%,95%CI 25-66)达客观缓解。

临床怎么用

  • 原文结论认为LOAd703联合白蛋白结合型紫杉醇加吉西他滨在晚期胰腺导管腺癌中可行且安全,未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic ductal adenocarcinoma is characterised by low immunogenicity and an immunosuppressive tumour microenvironment. LOAd703, an oncolytic adenovirus with transgenes encoding TMZ-CD40L and 4-1BBL, lyses cancer cells selectively, activates cytotoxic T cells, and induces tumour regression in preclinical models. The aim of this study was to evaluate the safety and feasibility of combining LOAd703 with chemotherapy for advanced pancreatic ductal adenocarcinoma. METHODS: LOKON001 was a non-randomised, phase 1/2 study conducted at the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA, and consisted of two arms conducted sequentially; the results of arm 1 are presented here. In arm 1, patients 18 years or older with previously treated or treatment-naive unresectable or metastatic pancreatic ductal adenocarcinoma were treated with standard 28-day cycles of intravenous nab-paclitaxel 125 mg/m2 plus gemcitabine 1000 mg/m2 (up to 12 cycles) and intratumoural injections of LOAd703 every 2 weeks. Patients were assigned using Bayesian optimal interval design to receive 500 μL of LOAd703 at 5 × 1010 (dose 1), 1 × 1011 (dose 2), or 5 × 1011 (dose 3) viral particles per injection, injected endoscopically or percutaneously into the pancreatic tumour or a metastasis for six injections. The primary endpoints were safety and treatment-emergent immune response in patients who received at least one dose of LOAd703, and antitumour activity was a secondary endpoint. This study was registered with ClinicalTrials.gov, NCT02705196, arm 2 is ongoing and open to new participants. FINDINGS: Between Dec 2, 2016, and Oct 17, 2019, 23 patients were assessed for eligibility, leading to 22 patients being enrolled. One patient withdrew consent, resulting in 21 patients (13 [62%] men and eight [38%] women) assigned to a dose group (three to dose 1, four to dose 2, and 14 to dose 3). 21 patients were evaluable for safety. Median follow-up time was 6 months (IQR 4-10), and data cutoff was Jan 5, 2023. The most common treatment-emergent adverse events overall were anaemia (96 [8%] of 1237 events), lymphopenia (86 [7%] events), hyperglycaemia (70 [6%] events), leukopenia (63 [5%] events), hypertension (62 [5%] events), and hypoalbuminaemia (61 [5%] events). The most common adverse events attributed to LOAd703 were fever (14 [67%] of 21 patients), fatigue (eight [38%]), chills (seven [33%]), and elevated liver enzymes (alanine aminotransferase in five [24%], alkaline phosphatase in four [19%], and aspartate aminotransferase in four [19%]), all of which were grade 1-2, except for a transient grade 3 aminotransferase elevation occurring at dose 3. A maximum tolerated dose was not reached, thereby establishing dose 3 as the highest-evaluated safe dose when combined with nab-paclitaxel plus gemcitabine. Proportions of CD8+ effector memory cells and adenovirus-specific T cells increased after LOAd703 injections in 15 (94%) of 16 patients for whom T-cell assays could be performed. Eight (44%, 95% CI 25-66) of 18 patients evaluable for activity had an objective response. INTERPRETATION: Combining LOAd703 with nab-paclitaxel plus gemcitabine in patients with advanced pancreatic ductal adenocarcinoma was feasible and safe. To build upon this novel chemoimmunotherapeutic approach, arm 2 of LOKON001, which combines LOAd703, nab-paclitaxel plus gemcitabine, and atezolizumab, is ongoing. FUNDING: Lokon Pharma, the Swedish Cancer Society, and the Swedish Research Council.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Musher BL, Rowinsky EK, Smaglo BG, et al. LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. Lancet Oncol. 2024. PMID: 38547893. doi:10.1016/S1470-2045(24)00079-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。